Novo Nordisk A/S（NVO）资讯与事件NVONovo Nordisk A/S

Novo Nordisk Shares Rise 2.9% to $39.23

Moderately bullish activity in Novo Nordisk (NVO), with shares up $1.10, or 2.9%, near $39.23. Options volume running well above average with 22k contracts traded and calls leading puts for a put/call ratio of 0.44, compared to a typical level near 0.85. Implied volatility (IV30) is higher by 0.7 points near 41.61,and below the 52wk median, suggesting an expected daily move of $1.03. Put-call skew steepened, indicating increased demand for downside protection.Looking ahead: Novo Nordisk (NVO) will report earnings after the close on None.Option markets are pricing in a 50% probability of a move greater than 0.0% or $0.00.

Evotec Appoints Joanna Holbrook as Chief Scientific Officer

Evotec (EVO) announced the appointment of Joanna Holbrook as chief scientific officer and member of the management board, effective November 1. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk (NVO).

Novo Nordisk Shares Up 0.39% to $37.55

Moderately bullish activity in Novo Nordisk (NVO), with shares up 14c, or 0.39%, near $37.55. Options volume relatively light with 6894 contracts traded and calls leading puts for a put/call ratio of 0.41, compared to a typical level near 0.79. Implied volatility (IV30) is higher by 0.9 points near 33.33,in the lowest 10% of observations over the past year, suggesting an expected daily move of $0.79. Put-call skew steepened, indicating increased demand for downside protection.